Ivabradine use was associated with a reduction of the primary composite endpoint in patients both with ( HR 0.82 , P = 0.023 ) and without renal dysfunction ( HR 0.81 , P < 0.001 ) at baseline ( P for interaction = 0.89 ) , and tolerability of ivabradine was comparable in the two groups .